Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02822531 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short and long-term outcome of levamisole in early versus late steroid responsive nephrotic syndrome: A single centre experience.
Pak J Med Sci
January 2025
Khemchand N Moorani, MBBS, MCPS, FCPS, IPNA Pediatr Nephrol fellowship Professor, Department of Pediatric Nephrology, The Kidney Centre Post Graduate Training Institute, Karachi. 197/9, Rafiqui Shaheed Road, Karachi-75530, Pakistan.
Objectives: To determine the effectiveness of Levamisole (Leva) in maintaining short-term and long-term remission in early steroid responders (ESRs) and late steroid responders (LSRs).
Methods: This retrospective study on 106 cohorts, aged 2-14 years with frequent-relapsing (FR) and steroid-dependent nephrotic syndrome (SDNS) who received Leva over 10-years (2012-2023), was carried out at tertiary care centre, Karachi from January-August 2023. Patients were categorized based on steroid response during first episode of NS as ESRs if complete remission (CR) was achieved within two weeks of daily steroid and LSRs if CR achieved between two-four weeks.
Effectiveness of levamisole in the treatment of patients with severe COVID-19: a randomized controlled clinical trial.
J Infect Dev Ctries
December 2024
Students' Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Introduction: Inflammation plays a role in coronavirus disease 2019 (COVID-19) pathophysiology and anti-inflammatory drugs may help reduce the disease severity. Levamisole is an anthelmintic drug with immunomodulatory and possible antiviral effects. This study aimed to evaluate the role of levamisole in the treatment of patients with COVID-19.
View Article and Find Full Text PDFKnowledge, attitudes and practices of Australian dairy goat farmers towards the control of gastrointestinal parasites.
Parasit Vectors
January 2025
Melbourne Veterinary School, The University of Melbourne, Werribee, VIC, 3030, Australia.
Background: Gastrointestinal parasites such as nematodes and coccidia are responsible for significant economic losses in the goat industry globally. An indiscriminate use of antiparasitic drugs, primarily registered for use in sheep and cattle, in goats has resulted in drug-resistant gastrointestinal parasites. Very little is known about the gastrointestinal parasite control practices used by Australian dairy goat farmers that are pivotal for achieving sustainable control of economically important parasites.
View Article and Find Full Text PDFFirst report of anthelmintic resistance among sheep in six farms from three governorates in Jordan.
Vet Parasitol Reg Stud Reports
January 2025
Department of Basic Medical Veterinary Sciences, Jordan University of Science & Technology, Irbid, Jordan.
This study aimed to identify the presence of gastrointestinal nematode populations resistant to albendazole, levamisole, and ivermectin in six farms located in three regions of Jordan (Irbid, Mafraq, and Ma'an). Infected sheep (40 per farm) with at least 100 eggs per gram were randomly divided into four groups (10 animals per group). Three groups were treated with ivermectin, albendazole, or levamisole while the fourth group was used as a negative control group.
View Article and Find Full Text PDFDrug combination assays using Caenorhabditis elegans as a model system.
J Pharmacol Toxicol Methods
January 2025
Instituto de Investigaciones Bioquímicas de Bahía Blanca, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS)-CONICET, 8000 Bahía Blanca, Argentina.
The C. elegans drug combination assay evaluates the effects of drug combinations in the nematode Caenorhabditis elegans, serving as a valuable tool to assess the efficacy of pharmaceutical agents and natural compounds. Using C.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!